Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

LAB-STEM CELLS

Kozono D., Nitta M., Sampetrean O., Kimberly N., Kushwaha D., Merzon D.

Animal Study on Face & Skin, Hip, published in Neuro Oncol (2012) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Neuro Oncol (2012)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC3488793

Abstract (original English)

INTRODUCTION: Recent evidence suggests that glioblastoma is driven by a subset of tumor initiating (TI) cells characterized by their capacity to form tumors in xenograft models and self-renew in vitro. These TI cells share many properties of neural stem/progenitor cells, including the expression of certain cell surface markers. With serial passage, many cells lose their capacity to TI. The transition between TI-proficient and - deficient states remains poorly understood. METHODS AND RESULTS: There are two theoretic models for the maintenance of TI states. In the “elite” model, TI activity is restricted to a predetermined subpopulation of cells. The alternative “stochastic” model suggests that any tumor cell has a finite chance of acquiring TI capacity through random fluctuations in cell physiology. To address this issue, we examined the TI capacity of distinct subclones isolated from a distinct glioblastoma line as well as the TI capacity of single cells derived from each distinct clone. We found that only a subset of subclones from a single glioblastoma line displayed capacity for TI, suggestive of the elite model. However, single cells derived from any single subclone exhibited a wide range of TI capacity, suggesting a stochastic component to this process. Transcriptome profiling of the subclones of differing TI revealed a gene signature associated with TI capacity. Analysis

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research